Long-term results and recurrence patterns from SCOPE-1: a phase II/III randomised trial of definitive chemoradiotherapy +/? cetuximab in oesophageal cancer

Crosby, Tom, Hurt, Christopher ORCID: https://orcid.org/0000-0003-1206-8355, Falk, S, Gollins, S, Staffurth, John ORCID: https://orcid.org/0000-0002-7834-3172, Ray, Ruby, Bridgewater, J A, Geh, J I, Cunningham, D, Blazeby, J, Roy, R, Maughan, Timothy, Griffiths, Gwyn and Mukherjee, Saptarshi 2017. Long-term results and recurrence patterns from SCOPE-1: a phase II/III randomised trial of definitive chemoradiotherapy +/? cetuximab in oesophageal cancer. British Journal of Cancer 116 (6) , pp. 709-716. 10.1038/bjc.2017.21

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (800kB) | Preview

Abstract

Background: The SCOPE-1 study tested the role of adding cetuximab to conventional definitive chemoradiotherapy (dCRT), and demonstrated greater toxicity and worse survival outcomes. We present the long-term outcomes and patterns of recurrence. Methods: SCOPE-1 was a phase II/III trial in which patients were randomised to cisplatin 60mgm�2 (day 1) and capecitabine 625mgm�2 bd (days 1–21) for four cycles þ/� cetuximab 400mgm�2 day 1 then by 250mgm�2 weekly. Radiotherapy consisted of 50 Gy/25# given concurrently with cycles 3 and 4. Recruitment was between February 2008 and February 2012, when the IDMC recommended closure on the basis of futility. Results: About 258 patients (dCRT¼129; dCRTþcetuximab (dCRTþC)¼129) were recruited from 36 centres. About 72.9% (n¼188) had squamous cell histology. The median follow-up (IQR) was 46.2 (35.9–48.3) months for surviving patients. The median overall survival (OS; months; 95% CI) was 34.5 (24.7–42.3) in dCRT and 24.7 (18.6–31.3) in dCRTþC (hazard ratio (HR)¼1.25, 95% CIs: 0.93–1.69, P¼0.137). Median progression-free survival (PFS; months; 95% CI) was 24.1 (15.3–29.9) and 15.9 (10.7–20.8) months, respectively (HR¼1.28, 95% CIs: 0.94–1.75; P¼0.114). On multivariable analysis only earlier stage, full-dose RT, and higher cisplatin dose intensity were associated with improved OS. Conclusions: The mature analysis demonstrates that the dCRT regimen used in the study provided useful survival outcomes despite its use in patients who were largely unfit for surgery or who had inoperable disease. Given the competing risk of systemic and local failure, future studies should continue to focus on enhancing local control as well as optimising systemic therapy.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > R Medicine (General)
Uncontrolled Keywords:	oesophageal; chemoradiotherapy; phase II/III; randomised; trial
Publisher:	Nature Publishing Group
ISSN:	0007-0920
Funders:	CRUK
Date of First Compliant Deposit:	27 February 2017
Date of Acceptance:	16 January 2017
Last Modified:	21 Oct 2023 01:10
URI:	https://orca.cardiff.ac.uk/id/eprint/98599

Citation Data

Cited 54 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item